Nigeria Neurology Clinical Trials Market Analysis

Nigeria Neurology Clinical Trials Market Executive Summary

Nigeria's Neurology Clinical Trials market is projected to grow from $4.71 Mn in 2022 to $7.79 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. According to Nigerian hospital-based retrospective research, the prevalence of neurological illnesses in Enugu is 48.7%. Moreover, a semiurban community prevalence research in Edo State, Nigeria, discovered a 45.4% incidence of neurological diseases.   Another community-based research in southwest Nigeria found a crude incidence of 352 neurological diseases per 1000 people. The prevalence of neurological illnesses is higher in developing nations due to factors such as a lack of healthcare facilities and professionals to treat the problems. In Nigeria, the aggregated gross prevalence of dementia was 4.9% with women having a substantially higher prevalence than males.

Nigeria's neurology clinical trials industry is still in its early stages, with less activity compared to other areas. Nonetheless, multiple variables point to the possibility of future expansion in this field. Nigeria suffers from a high prevalence of neurological ailments such as stroke, epilepsy, and neurodegenerative diseases such as Parkinson's and Alzheimer's. Because of the high illness load, there is a considerable need for novel and creative therapies, making the nation an appealing venue for clinical trials in the neurology field. Although the Nigerian neurology clinical trials industry is still in its infancy, there is room for expansion owing to the country's high illness burden, vast and diversified population, and well-established healthcare system. Yet, in order to realise the full potential of this market, legislative and ethical constraints, as well as logistical difficulties, must be addressed.

Market Dynamics

Market Growth Drivers

Many reasons drive the Nigerian neurology clinical trials market, including the country's high prevalence of neurological illnesses, the rising need for novel therapies, and the existence of a well-established healthcare system. Nigeria has a high prevalence of neurological illnesses, such as stroke, epilepsy, and neurodegenerative diseases including Parkinson's and Alzheimer's. This high illness burden necessitates the development of innovative and effective therapies, making Nigeria. Moreover, rising investment in clinical research, notably in neurology, is being driven by Nigeria's growing desire for novel medicines. Furthermore, Nigeria's well-established healthcare system, which includes an increasing number of hospitals and clinics, serves as a solid basis for clinical trial infrastructure.

Market Restraints

There are also various constraints that may impede the development of the Nigerian neurology clinical trials market. One key impediment is the country's lack of regulatory and ethical structures to oversee clinical trials. Although Nigeria has made progress in building these frameworks, more effort has to be done to guarantee that clinical trials in the nation are safe, ethical, and transparent. Moreover, there are practical obstacles connected with conducting clinical trials in Nigeria, such as concerns with infrastructure, transportation, and communication. These obstacles may raise the expense and difficulty of conducting clinical trials in the nation, discouraging some sponsors from entering the market. Furthermore, a lack of clinical research funding and resources in Nigeria may hinder the potential of local researchers to perform high-quality clinical trials in the neurology domain, further limiting the market's development.

Competitive Landscape

Key Players

• Pfizer Inc.
• Novartis AG
• Merck & Co.
• Sanofi
• Roche
• AstraZeneca plc
• Johnson & Johnson

Notable Insights

September 2021, Aminu Kano Teaching Hospital (AKTH), Bayero University Kano (BUK), and Vanderbilt Institute for Global Health (VIGH) in Kano, Nigeria, have a long history of NIH-funded partnerships in juvenile brain diseases. These three universities are collaborating on a new $1.2 million, five-year training programme supported by the National Institutes of Health's (NIH) Fogarty International Center's Chronic, Noncommunicable Diseases and Disorders Across the Lifespan Training Program. The new funding will help Nigerian researchers study child neurology and epilepsy.

Healthcare Policies and Regulatory Landscape

The National Agency for Food and Drug Administration and Control (NAFDAC) is in charge of protocol evaluation and clinical trial approvals before they are performed in Nigeria. It is also in charge of inspecting trial locations and monitoring the conduct of permitted research to guarantee that the participants' well-being and safety are safeguarded and that valid data is produced from the study.

The National Health Research Ethics Committee (NHREC) is in charge of accrediting Independent Ethics Committees (IECs) and/or Institutional Review Boards (IRBs) that provide ethical advice on research protocols based on the number of trial sites participating.